Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-9 (MMP-9), and its specific tissue inhibitor - tissue inhibitor of metalloproteinases-1 (TIMP-1) may play an important role in the pathogenesis and spread of cancer. We investigated the plasma levels of M-CSF, MMP-9, and TIMP-1 in comparison with a commonly accepted tumor marker CA 15-3 in breast cancer patients and in control groups. Methods: The cohort included 110 breast cancer patients in groups at stages I-IV. The control group consisted of 50 healthy volunteers and 50 benign tumor patients. Plasma levels of M-CSF, MMP-9, and TIMP-1 were determined by using ELISA, while CA 15-3 concentrations were determined by using chemiluminescent microparticle immunoassay (CMIA). Results: The results showed significant differences in concentrations of the analyzed parameters and in levels of CA 15-3 between the groups of breast cancer patients and the two control groups. Diagnosis using these markers was equal to that using CA 15-3 in terms of sensitivity, predictive values of positive and negativetest results (PPV, NPV) and area under the ROC curve (AUC) in the studied groups. The diagnostic specificities of MMP-9, TIMP-1, M-CSF, and CA 15-3 showed equally high values (95%). The combined use of all tested parameters with CA 15-3 resulted in increased sensitivity, NPV, and AUC, especially in the combination of M-CSF with tumor markers (76%, 64%, and 0.8653). Conclusions: These findings suggest the tested parameters are useful in the diagnosis of breast cancer patients (except stage I), when combined with CA 15-3.
Abstract
Background: Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-9 (MMP-9), and its specific tissue inhibitor - tissue inhibitor of metalloproteinases-1 (TIMP-1) may play an important role in the pathogenesis and spread of cancer. We investigated the plasma levels of M-CSF, MMP-9, and TIMP-1 in comparison with a commonly accepted tumor marker CA 15-3 in breast cancer patients and in control groups. Methods: The cohort included 110 breast cancer patients in groups at stages I-IV. The control group consisted of 50 healthy volunteers and 50 benign tumor patients. Plasma levels of M-CSF, MMP-9, and TIMP-1 were determined by using ELISA, while CA 15-3 concentrations were determined by using chemiluminescent microparticle immunoassay (CMIA). Results: The results showed significant differences in concentrations of the analyzed parameters and in levels of CA 15-3 between the groups of breast cancer patients and the two control groups. Diagnosis using these markers was equal to that using CA 15-3 in terms of sensitivity, predictive values of positive and negativetest results (PPV, NPV) and area under the ROC curve (AUC) in the studied groups. The diagnostic specificities of MMP-9, TIMP-1, M-CSF, and CA 15-3 showed equally high values (95%). The combined use of all tested parameters with CA 15-3 resulted in increased sensitivity, NPV, and AUC, especially in the combination of M-CSF with tumor markers (76%, 64%, and 0.8653). Conclusions: These findings suggest the tested parameters are useful in the diagnosis of breast cancer patients (except stage I), when combined with CA 15-3.
참고문헌 (29)
- American Cancer Society, "Facts & Figures 2014", American Cancer Society, 4~ (2014)
- Trichopoulos D, "Early life events and conditions and breast cancer risk: from epidemiology to etiology", Int J Cancer, 122, pp.481~485 (2008)
- Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J ClinOncol, 25, pp.5287~5312 (2007)
- Fingleton B, "Matrix metalloproteinases: roles in cancer and metastasis", Front Biosci, 11, pp.479~491 (2006)
- Pellikainen JM, "Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis", Clin Cancer Res, 10, pp.7621~7628 (2004)
- Brew K, "Tissue inhibitors of metalloproteinases: evolution, structure and function", BiochimBiophysActa, 1477, pp.267~283 (2000)
- Baker AH, "Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis", J Clin Invest, 101, pp.1478~1487 (1998)
- Talvensaari-Mattila A, "High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma", Breast Cancer Res Treat, 89, pp.29~34 (2005)
- Lin EY, "The macrophage growth factor CSF-1 in mammary gland development and tumor progression", J Mammary Gland BiolNeoplasia, 7, pp.147~162 (2002)
- Sobin LH, "TNM classification of malignant tumours", pp.181~183 (2011), John Wiley & Sons
- Jemal A, "Cancer statistics, 2003", CACancer J Clin, 53, pp.5~26 (2003)
- Ławicki S, "Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients", Folia HistochemCytobiol, 50, pp.213~219 (2012)
- Ławicki S, "The plasma levels and diagnostics utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri", Pol MerkurLekarski, 28, pp.354~358 (2010)
- Ławicki S, "Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients", Growth Factors, 30, pp.357~366 (2012)
- Czygier M, "The plasma level of sL-selectin, myeloperoxidase (MPO) and granulocyte-colony stimulating factor (G-CSF) in breast cancer patients after surgery", PrzeglLek, 66, pp.433~436 (2009)
- Vasiliades G, "Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer", Int J Biol Markers, 27, pp.186~194 (2012)
- Bahar B, "Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis", Asian Pac J Cancer Prev, 11, pp.709~712 (2010)
- McDermott RS, "Circulating macrophage colony stimulating factor as a marker of tumour progression", Eur Cytokine Netw, 13, pp.121~127 (2002)
- Kaciński BM, "CSF-1 and its receptor in ovarian, endometrial and breast cancer", Ann Med, 27, pp.79~85 (1995)
- Scholl SM, "Circulating levels of the macrophage-colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study", Breast Cancer Res Treat, 39, pp.275~283 (1996)
- Visse R, "Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry", Circ Res, 92, pp.827~839 (2003)
- Giannelli G, "Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients", Int J Cancer, 109, pp.782~785 (2004)
- Jinga DC, "MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors", J Cell Mol Med, 10, pp.499~510 (2006)
- Wu ZS, "Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer", Int J Cancer, 122, pp.2050~2056 (2008)
- Voorzanger-Rousselot N, "Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation", Br J Cancer, 95, pp.506~514 (2006)
- Ławicki S, "VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve", Growth Factors, 31, pp.98~105 (2013)
- Ławicki S, "The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients", ClinChimActa, 371, pp.112~116 (2006)
- Iwata H, "Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas", Jpn J Cancer Res, 87, pp.602~611 (1996)
- McCarthy K, "High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer", Int J Cancer, 84, pp.44~48 (1999)